Across TCGA pan-cancer cohorts, MIR625 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of MIR625’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where MIR625 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR625 is over-expressed in tumor.

STAD are the cancer types where MIR625 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MIR625 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	All	All	+0.186	.017	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: MIR625 RNA expression & survival · all MIR625 data types